[{"abstract": "It is impossible to assess the impact of tax rates on labor supply without acknowledging both unpaid work at home and the growing underground economy, an economist writes.", "web_url": "https://economix.blogs.nytimes.com/2013/11/04/the-sloth-effect/", "snippet": "It is impossible to assess the impact of tax rates on labor supply without acknowledging both unpaid work at home and the growing underground economy, an economist writes.", "lead_paragraph": "Nancy Folbre is professor emerita of economics at the University of Massachusetts, Amherst.", "source": "The New York Times", "multimedia": [], "headline": {"main": "The Sloth Effect", "kicker": "Economix", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Economics (Theory and Philosophy)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Labor and Jobs", "rank": 2, "major": "N"}, {"name": "subject", "value": "Parenting", "rank": 3, "major": "N"}, {"name": "subject", "value": "Taxation", "rank": 4, "major": "N"}, {"name": "persons", "value": "Heckman, James J", "rank": 5, "major": "N"}], "pub_date": "2013-11-04T04:01:37+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "subsection_name": "Economy", "byline": {"original": "By Nancy Folbre", "person": [{"firstname": "Nancy", "middlename": null, "lastname": "Folbre", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/93394a71-a3ff-51fb-97f4-477dc9eff42e", "word_count": 813, "uri": "nyt://article/93394a71-a3ff-51fb-97f4-477dc9eff42e"}, {"abstract": "Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.", "web_url": "https://www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html", "snippet": "Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.", "lead_paragraph": "Johnson & Johnson has agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the antipsychotic drug Risperdal to older adults, children and people with developmental disabilities, the Justice Department said on Monday. ", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-articleLarge.jpg", "height": 392, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2013/11/05/business/Drug2/Drug2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 392}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-jumbo.jpg", "height": 669, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-superJumbo.jpg", "height": 1339, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2013/11/05/business/Drug2/Drug2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "J.&J. to Pay $2.2 Billion in Risperdal Settlement", "kicker": null, "content_kicker": null, "print_headline": "J.&J. to Pay $2.2 Billion In Risperdal Settlement", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Johnson & Johnson", "rank": 1, "major": "N"}, {"name": "persons", "value": "Thomas, Katie", "rank": 2, "major": "N"}, {"name": "subject", "value": "Fines (Penalties)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "ADVERTISING AND MARKETING", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mental Health and Disorders", "rank": 6, "major": "N"}], "pub_date": "2013-11-04T17:26:12+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Katie Thomas", "person": [{"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/5c86401d-cb0c-52ea-ba9b-ec51b61c2f6e", "word_count": 1113, "uri": "nyt://article/5c86401d-cb0c-52ea-ba9b-ec51b61c2f6e"}]